365 related articles for article (PubMed ID: 26463091)
1. Emerging immunotherapies in ovarian cancer.
Ojalvo LS; Nichols PE; Jelovac D; Emens LA
Discov Med; 2015 Sep; 20(109):97-109. PubMed ID: 26463091
[TBL] [Abstract][Full Text] [Related]
2. New Approaches for Immune Directed Treatment for Ovarian Cancer.
Hardwick N; Frankel PH; Cristea M
Curr Treat Options Oncol; 2016 Mar; 17(3):14. PubMed ID: 26942589
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in Ovarian Cancer.
Wang W; Liu JR; Zou W
Surg Oncol Clin N Am; 2019 Jul; 28(3):447-464. PubMed ID: 31079799
[TBL] [Abstract][Full Text] [Related]
4. Novel target antigens for dendritic cell-based immunotherapy against ovarian cancer.
Cannon MJ; O'Brien TJ; Underwood LJ; Crew MD; Bondurant KL; Santin AD
Expert Rev Anticancer Ther; 2002 Feb; 2(1):97-105. PubMed ID: 12113075
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy in ovarian cancer.
Krishnan V; Berek JS; Dorigo O
Curr Probl Cancer; 2017; 41(1):48-63. PubMed ID: 28169004
[TBL] [Abstract][Full Text] [Related]
6. Opportunities in immunotherapy of ovarian cancer.
Coukos G; Tanyi J; Kandalaft LE
Ann Oncol; 2016 Apr; 27 Suppl 1(Suppl 1):i11-i15. PubMed ID: 27141063
[TBL] [Abstract][Full Text] [Related]
7. Understanding the cross-talk between ovarian tumors and immune cells: mechanisms for effective immunotherapies.
Chiriva-Internati M; Mirandola L; Kast WM; Jenkins MR; Cobos E; Cannon MJ
Int Rev Immunol; 2011; 30(2-3):71-86. PubMed ID: 21557635
[TBL] [Abstract][Full Text] [Related]
8. Understanding dendritic cell immunotherapy in ovarian cancer.
Drakes ML; Stiff PJ
Expert Rev Anticancer Ther; 2016 Jun; 16(6):643-52. PubMed ID: 27078511
[TBL] [Abstract][Full Text] [Related]
9. Ovarian cancer biology and immunotherapy.
Latha TS; Panati K; Gowd DS; Reddy MC; Lomada D
Int Rev Immunol; 2014 Oct; 33(5):428-40. PubMed ID: 24911597
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy opportunities in ovarian cancer.
Chu CS; Kim SH; June CH; Coukos G
Expert Rev Anticancer Ther; 2008 Feb; 8(2):243-57. PubMed ID: 18279065
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in ovarian cancer.
Odunsi K
Ann Oncol; 2017 Nov; 28(suppl_8):viii1-viii7. PubMed ID: 29232467
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors.
De Felice F; Marchetti C; Palaia I; Musio D; Muzii L; Tombolini V; Panici PB
J Immunol Res; 2015; 2015():191832. PubMed ID: 26236750
[TBL] [Abstract][Full Text] [Related]
13. Emerging Role and Future Directions of Immunotherapy in Advanced Ovarian Cancer.
Chodon T; Lugade AA; Battaglia S; Odunsi K
Hematol Oncol Clin North Am; 2018 Dec; 32(6):1025-1039. PubMed ID: 30390758
[TBL] [Abstract][Full Text] [Related]
14. Ovarian Cancer Immunotherapy: Turning up the Heat.
Ghisoni E; Imbimbo M; Zimmermann S; Valabrega G
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31208030
[TBL] [Abstract][Full Text] [Related]
15. Current approaches in ovarian cancer vaccines.
Reinartz S; Wagner U
Minerva Ginecol; 2004 Dec; 56(6):515-27. PubMed ID: 15729204
[TBL] [Abstract][Full Text] [Related]
16. Novel immunotherapeutic strategies in gynecologic oncology. Dendritic cell-based immunotherapy for ovarian cancer.
Santin AD; Bellone S; Underwood LJ; O'Brien TJ; Ravaggi A; Pecorelli S; Cannon MJ
Minerva Ginecol; 2002 Apr; 54(2):133-44. PubMed ID: 12032451
[TBL] [Abstract][Full Text] [Related]
17. The Role of the Immune System in Ovarian Cancer and Implications on Therapy.
Menderes G; Schwab CL; Black J; Santin AD
Expert Rev Clin Immunol; 2016 Jun; 12(6):681-95. PubMed ID: 26821930
[TBL] [Abstract][Full Text] [Related]
18. Targeting the programmed cell death-1 pathway in breast and ovarian cancer.
Emens LA; Kok M; Ojalvo LS
Curr Opin Obstet Gynecol; 2016 Apr; 28(2):142-7. PubMed ID: 26881392
[TBL] [Abstract][Full Text] [Related]
19. [Immunotherapy for cancer--modern immunologic strategies in oncology].
Halama N; Zoernig I; Jäger D
Dtsch Med Wochenschr; 2008 Oct; 133(41):2105-8. PubMed ID: 18985564
[TBL] [Abstract][Full Text] [Related]
20. Immune therapy for ovarian cancer: promise and pitfalls.
Thibodeaux SR; Curiel TJ
Int Rev Immunol; 2011; 30(2-3):102-19. PubMed ID: 21557637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
